565 related articles for article (PubMed ID: 17877652)
21. Once-Daily OROS Hydromorphone for Management of Cancer Pain: an Open-Label, Multi-Center, Non-Interventional Study.
Park CK; Kang HW; Oh IJ; Kim YC; Kim YK; Na KJ; Ahn SJ; Kim TO; Choi YJ; Song GA; Lee MK
J Korean Med Sci; 2016 Dec; 31(12):1914-1921. PubMed ID: 27822929
[TBL] [Abstract][Full Text] [Related]
22. Safety and tolerability of OROS® hydromorphone ER in adults with chronic noncancer and cancer pain: pooled analysis of 13 studies.
Hale ME; Wallace MS; Taylor DR; Kutch M; Nalamachu S
J Opioid Manag; 2012; 8(5):299-314. PubMed ID: 23247907
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety profile of a single dose of hydromorphone compared with morphine in older adults with acute, severe pain: a prospective, randomized, double-blind clinical trial.
Chang AK; Bijur PE; Baccelieri A; Gallagher EJ
Am J Geriatr Pharmacother; 2009 Feb; 7(1):1-10. PubMed ID: 19281935
[TBL] [Abstract][Full Text] [Related]
24. Open-label study on the long-term efficacy, safety, and impact on quality of life of OROS hydromorphone ER in patients with chronic low back pain.
Wallace M; Thipphawong J
Pain Med; 2010 Oct; 11(10):1477-88. PubMed ID: 21199302
[TBL] [Abstract][Full Text] [Related]
25. The role of OROS hydromorphone in the management of cancer pain.
Gardner-Nix J; Mercadante S
Pain Pract; 2010; 10(1):72-7. PubMed ID: 19863749
[TBL] [Abstract][Full Text] [Related]
26. An open-label, 1-year extension study of the long-term safety and efficacy of once-daily OROS(R) hydromorphone in patients with chronic cancer pain.
Hanna M; Tuca A; Thipphawong J
BMC Palliat Care; 2009 Sep; 8():14. PubMed ID: 19754935
[TBL] [Abstract][Full Text] [Related]
27. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
28. Dose proportionality and pharmacokinetics of extended-release (OROS®) hydromorphone: a phase 1, open-label, randomized, crossover study in healthy Taiwanese subjects.
Vandenbossche J; Richards HM; Lu CC; Richarz U
Int J Clin Pharmacol Ther; 2014 Mar; 52(3):217-26. PubMed ID: 24472398
[TBL] [Abstract][Full Text] [Related]
29. Factors affecting acceptability of titrated oxymorphone extended release in chronic low back pain - an individual patient analysis.
Peniston JH; Xiang Q; Gould EM
Curr Med Res Opin; 2010 Aug; 26(8):1861-71. PubMed ID: 20521870
[TBL] [Abstract][Full Text] [Related]
30. [Oral osmotic hydromorphone (OROS) in patients with chronic severe pain due to osteoarthritis under daily routine conditions].
Müller-Schwefe GH; Blimke B; Hesselbarth S; Giesecke T
MMW Fortschr Med; 2014 Apr; 156 Suppl 1():23-9. PubMed ID: 24930329
[TBL] [Abstract][Full Text] [Related]
31. [Pharmacotherapy of chronic, non-tumour related pain. Efficacy, tolerability and patient benefit of an oral osmotic system with hydromorphone].
Sabatowski R; Giesecke T
MMW Fortschr Med; 2007 Sep; 149 Suppl 3():119-24. PubMed ID: 17955789
[TBL] [Abstract][Full Text] [Related]
32. Comparative effects of morning vs. evening dosing of extended-release hydromorphone on sleep physiology in patients with low back pain: a pilot study.
Webster LR; Smith MD; Mackin S; Iverson M
Pain Med; 2015 Mar; 16(3):460-71. PubMed ID: 25279807
[TBL] [Abstract][Full Text] [Related]
33. Hydromorphone-OROS formulation.
Goforth HW
Expert Opin Pharmacother; 2010 May; 11(7):1207-14. PubMed ID: 20402557
[TBL] [Abstract][Full Text] [Related]
34. Effectiveness and gastrointestinal tolerability during conversion and titration with once-daily OROS® hydromorphone extended release in opioid-tolerant patients with chronic low back pain.
Hale ME; Nalamachu SR; Khan A; Kutch M
J Pain Res; 2013; 6():319-29. PubMed ID: 23658495
[TBL] [Abstract][Full Text] [Related]
35. Safety and Tolerability of Once-Daily OROS(®) hydromorphone extended-release in opioid-tolerant adults with moderate-to-severe chronic cancer and noncancer pain: pooled analysis of 11 clinical studies.
Nalamachu SR; Kutch M; Hale ME
J Pain Symptom Manage; 2012 Dec; 44(6):852-65. PubMed ID: 22795050
[TBL] [Abstract][Full Text] [Related]
36. Oral hydromorphone extended-release.
Guay DR
Consult Pharm; 2010 Dec; 25(12):816-28. PubMed ID: 21172762
[TBL] [Abstract][Full Text] [Related]
37. Comparative efficacy of oral extended-release hydromorphone and immediate-release hydromorphone in patients with persistent moderate to severe pain: two randomized controlled trials.
Grosset AB; Roberts MS; Woodson ME; Shi M; Swanton RE; Reder RF; Buckley BJ
J Pain Symptom Manage; 2005 Jun; 29(6):584-94. PubMed ID: 15963867
[TBL] [Abstract][Full Text] [Related]
38. Clinical experience with transdermal and orally administered opioids in palliative care patients--a retrospective study.
Clemens KE; Klaschik E
Jpn J Clin Oncol; 2007 Apr; 37(4):302-9. PubMed ID: 17519302
[TBL] [Abstract][Full Text] [Related]
39. Use of hydromorphone, with particular reference to the OROS formulation, in the elderly.
Lussier D; Richarz U; Finco G
Drugs Aging; 2010 Apr; 27(4):327-35. PubMed ID: 20361803
[TBL] [Abstract][Full Text] [Related]
40. [Pain reduced and quality of life improved by sustained-release hydromorphone. Results of an observational study].
Sittig HB
MMW Fortschr Med; 2004 Dec; 146(49):45. PubMed ID: 15646717
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
